密度	1.31±0.1 g/cm3 (20 ºC

没有数据	没有数据

来源	SDS样本
没有数据	没有数据

产品合成路线

更多

名称	CAS号

更多

文章

同行评议文献

Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.Kanyu Miyamoto et al.Clinical and experimental nephrology, 14(2), 164-167 (2009-11-17) A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.Mark V Sherrid et al.Progress in cardiovascular diseases, 54(6), 483-492 (2012-06-13) Negative ionotropic agents for the treatment of left ventricular outflow tract obstruction due to sigmoid septum and concentric left ventricular hypertrophy.Isuru Ranasinghe et al.Heart, lung & circulation, 20(9), 579-586 (2011-06-21) Possible acute and chronic synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy: a case report.Shintaro Haruki et al.European journal of heart failure, 12(1), 94-97 (2009-11-28) Prospective comparative study of intravenous cibenzoline and disopyramide therapy in the treatment of paroxysmal atrial fibrillation after cardiovascular surgery.Takashi Komatsu et al.Circulation journal : official journal of the Japanese Circulation Society, 74(9), 1859-1865 (2010-07-16) [Drug treatment for hypertrophic cardiomyopathy].Pierre Gibelin Presse medicale (Paris, France : 1983), 38(6), 1001-1004 (2009-05-19) Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature.M Abe et al.Clinical nephrology, 76(5), 401-406 (2011-10-18) Beers criteria for potentially inappropriate medication use in older adults.Sandra N Berryman et al.Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 21(3), 129-132 (2012-08-08) Impact of probe compound in MRP2 vesicular transport assays.Heidi Kidron et al.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 46(1-2), 100-105 (2012-03-13) Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms.Koji Nishi et al.The Journal of biological chemistry, 286(16), 14427-14434 (2011-02-26) Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.Katsuya Kajimoto et al.The American journal of cardiology, 106(9), 1307-1312 (2010-10-30) Combined effect of disopyramide and erythromycin on ventricular repolarization in dogs with complete atrioventricular block.Ichiro Watanabe et al.International heart journal, 52(6), 393-397 (2011-12-23) Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide.Anthony A Philippakis et al.Circulation, 125(14), 1821-1824 (2012-04-12) Evaluation of selective competitive binding of basic drugs to alpha1-acid glycoprotein variants.Junko Ishizaki et al.Biological & pharmaceutical bulletin, 33(1), 95-99 (2010-01-05) Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?Dan Musat et al.Progress in cardiovascular diseases, 54(6), 535-542 (2012-06-13) Quantitative assessment of cibenzoline administration for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis.Mutsumi Miyakoshi et al.Journal of cardiology, 54(1), 86-92 (2009-07-28) Drug-induced hypoglycaemia. Prescrire international, 18(100), 67-67 (2009-07-10) Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.Hiroshi Asajima et al.European journal of clinical pharmacology, 68(3), 331-333 (2011-09-08) [Disopyramide phosphate: the electrophysiological mechanisms of its anti-arrhythmia action and its use in clinical practice].A A Grosu Kardiologiia, 25(5), 114-118 (1985-05-01) Molecular determinants of hERG potassium channel inhibition by disopyramide.Aziza El Harchi et al.Journal of molecular and cellular cardiology, 52(1), 185-195 (2011-10-13) High efficacy of disopyramide in the management of ventricular fibrillation storms in a patient with Brugada syndrome.Shunichiro Sumi et al.Pacing and clinical electrophysiology : PACE, 33(6), e53-e56 (2010-01-12) Pharmacological prevention and termination of focal atrial fibrillation.Annerie M E Moers et al.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14(3), 426-430 (2011-09-22) A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.R Di Bianco et al.Angiology, 38(2 Pt 2), 174-183 (1987-02-01) Monitoring disopyramide, lidocaine, and quinidine by micellar liquid chromatography.Enrique Ochoa-Aranda et al.Journal of AOAC International, 94(2), 537-542 (2011-05-14) Recurrent Torsade de Pointes during mild hypothermia therapy for a survivor of sudden cardiac arrest due to drug-induced long-QT syndrome.Tomohiro Matsuhashi et al.Journal of cardiovascular electrophysiology, 21(4), 462-463 (2009-10-23) Cardiopulmonary exercise testing diagnosis of myocardial suppression.R C F Sinclair et al.Anaesthesia, 64(7), 788-789 (2009-07-25) Provokable left ventricular outflow tract obstruction in a patient without hypertrophy.Ferdinando Pasquale et al.Nature reviews. Cardiology, 6(4), 313-316 (2009-04-09)

备注